Literature DB >> 12379506

Impaired endothelial dysfunction in diabetes mellitus rats was restored by oral administration of prostaglandin I2 analogue.

K Matsumoto1, R Morishita, N Tomita, A Moriguchi, K Yamasaki, M Aoki, K Matsumoto1, T Nakamura, J Higaki, T Ogihara.   

Abstract

We have previously reported that a decrease in hepatocyte growth factor (HGF), which has many protective functions against endothelial damage by high d-glucose, might be a trigger of endothelial injury. However, the regulation of vascular HGF in diabetes mellitus (DM) has not been clarified in vivo, although vascular disease is frequently observed in DM patients. In addition, our previous report revealed that a prostaglandin I(2) (PGI(2)) analogue prevented endothelial cell death through the induction of vascular HGF production in cultured human epithelial cells. Thus, in this study, we examined the effects of a PGI(2) analogue in the regulation of the local HGF system using DM rats. A PGI(2) analogue (beraprost sodium; 300 and 600 micro g/kg per day) or vehicle was administered to 16-week-old DM rats induced by administration of streptozotocin for 28 days. Endothelial function was evaluated by the vasodilator response to acetylcholine, and the expression of vascular HGF mRNA was measured by Northern blotting. Of importance, expression of HGF mRNA was significantly decreased in the blood vessels of DM rats as compared with non-DM (P<0.01). In addition, the in vitro vasodilator response of the abdominal aorta to acetylcholine was markedly impaired in DM rats. Importantly, the vasodilator response was restored by PGI(2) treatment in a dose-dependent manner (P<0.01), whereas N(omega)-nitro-l-arginine methyl ester inhibited the restoration of endothelial function. Of particular interest, vascular HGF mRNA and protein were significantly increased in the blood vessels of DM rats treated with PGI(2) as compared with vehicle. Similarly, an increase in HGF protein was also confirmed by immunohistochemical analysis. In addition, the specific HGF receptor, c-met, was also increased by PGI(2) treatment. Overall, this study demonstrated that treatment with a PGI(2) analogue restored endothelial dysfunction in DM rats, accompanied by the induction of vascular HGF and c-met expression. Increased local vascular HGF production by a PGI(2) analogue may prevent endothelial injury, potentially resulting in the improvement of endothelial dysfunction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379506     DOI: 10.1677/joe.0.1750217

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  6 in total

1.  The roles of peroxidase and phospholipase A2 activities of peroxiredoxin 6 in protecting pulmonary microvascular endothelial cells against peroxidative stress.

Authors:  Yu-Chin Lien; Sheldon I Feinstein; Chandra Dodia; Aron B Fisher
Journal:  Antioxid Redox Signal       Date:  2011-12-23       Impact factor: 8.401

2.  Role of endothelium-dependent hyperpolarisation and prostacyclin in diabetes.

Authors:  Siti Safiah Mokhtar; Aida Hanum Ghulam Rasool
Journal:  Malays J Med Sci       Date:  2015 Mar-Apr

3.  Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes.

Authors:  Hooi Hooi Ng; Chen Huei Leo; Darnel Prakoso; Chengxue Qin; Rebecca H Ritchie; Laura J Parry
Journal:  Sci Rep       Date:  2017-01-09       Impact factor: 4.379

4.  8th Asian PAD Workshop.

Authors: 
Journal:  Ann Vasc Dis       Date:  2017-12-25

5.  The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats.

Authors:  Nahoko Sato; Masayuki Kaneko; Mitsutaka Tamura; Hajimu Kurumatani
Journal:  Diabetes       Date:  2010-01-12       Impact factor: 9.461

6.  Contribution of Cyclooxygenase End Products and Oxidative Stress to Intrahepatic Endothelial Dysfunction in Early Non-Alcoholic Fatty Liver Disease.

Authors:  Francisco Javier Gonzalez-Paredes; Goretti Hernández Mesa; Dalia Morales Arraez; Raquel Marcelino Reyes; Beatriz Abrante; Felicitas Diaz-Flores; Eduardo Salido; Enrique Quintero; Manuel Hernández-Guerra
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.